NEXGENRX INC (NXG.CA) Stock News

NexgenRx Announces Financial Results for Q3 2021 with Increased Positive EBITDA and Free Cash Flow

TORONTO, ON / ACCESSWIRE / November 19, 2021 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2021. Despite the continuing uncertainties resulting from the COVID-19 pandemic, the Company continued to generate increased positive EBITDA and free cash flow; operated effectively and safely through the pandemic, lowered costs, and finished the quarter with

NexgenRx Announces Expansion of Leadership Team

Addition of two senior executives, John Gray and Mark Payne to the leadership team signals continued focus on technology operations and strategic innovation partnerships TORONTO, ON / ACCESSWIRE / August 24, 2021 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the addition of two new leaders to its management team: John Gray, Vice-President, Strategic Growth Opportunities, and Mark Payne, Vice-President, IT. John Gray joins

NexgenRx Announces 2020 Q1 Interim Results

NexgenRx Announces 2019 Annual Results

NexgenRx Announces Q3 2019 Results

NexgenRx Announces Financial Results for Q2 2021 With Continued Growth in Revenues and Adjusted EBITDA

TORONTO, ON / ACCESSWIRE / August 18, 2021 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2021, which continue to build upon the Company's positive 2020 year-end and Q1 2021 results. Despite the continued lockdowns due to COVID-19 throughout the second quarter, the Company's Q2 revenue was $2,761,544, an increase of $356,305 (14.8%) compared to

NexgenRx Announces Annual Meeting Results

TORONTO, ON / ACCESSWIRE / June 10, 2021 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the results of its annual and special meeting (the "Meeting") of shareholders, which was held on Thursday, June 10, 2021. The Meeting was held, in part, to deliver the annual financial statements and related management's discussion and analysis of the Company, fix and appoint the directors of the Company, appoint the Company's auditors

NexgenRx Announces Financial Results for Q1 2021 with Continued EBITDA and Net Profit Growth

TORONTO, ON / ACCESSWIRE / May 26, 2021 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the first quarter ended March 31, 2021, which continue to build upon the Company's 2020 results, which showed record growth in both EBITDA and net profit. For Q1 2021, the Company recorded EBITDA of $693,699, representing an increase of $103,806 over same prior year

NexgenRx Announces Q2 2019 Results

NexgenRx Announces Q3 2020 Results

TORONTO, ON / ACCESSWIRE / November 19, 2020 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the third quarter ended September 30, 2020. Revenues of $2,651,682 were generated during the period, resulting in net income of $509,843 and EBITDA of $795,169, which represented increases of $728,561 and $674,126, respectively, over the third quarter of the prior year. Transaction

NexgenRx Announces 2020 Q2 Interim Results

TORONTO, ON / ACCESSWIRE / August 20, 2020 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the quarter ended June 30, 2020. Despite the many challenges arising due to the COVID-19 pandemic, Q2 2020 ended with excellent financial results for the Company, generating net income and EBITDA of $479,104 and $772,389 respectively, an increase of $514,042 and

NexgenRx Announces Amendment of Share Capital, Creation and Issuance of Series 1 Preferred Shares

NexgenRx Announces Debt Re-Structuring